Posted by Michael Wonder on 02 Nov 2021
Otsuka submits initial marketing authorization application to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
29 October 2021 - Otsuka announces that Otsuka Pharmaceutical Netherlands has submitted an initial marketing authorisation application to the EMA for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anaemia associated with chronic kidney disease in adults.
Vadadustat was developed in Europe under a collaboration and license agreement between Akebia Therapeutics and Otsuka.
